deltatrials
Terminated PHASE1 INTERVENTIONAL 14-arm NCT06579300

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

Sponsor: AbbVie

Updated 7 times since 2024 Last updated: Oct 29, 2025 Started: Sep 4, 2024 Primary completion: Sep 3, 2025 Completion: Sep 3, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic considerations

This PHASE1 trial investigates Healthy Volunteer and is currently terminated or withdrawn. AbbVie leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshotRecruiting~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshotRecruiting~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshotTerminated

Change History

7 versions recorded
  1. Nov 2025 — Present [monthly]

    Terminated PHASE1

    Status: SuspendedTerminated

  2. Oct 2025 — Nov 2025 [monthly]

    Suspended PHASE1

    Status: Active Not RecruitingSuspended

  3. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1

    Status: RecruitingActive Not Recruiting

  4. Jul 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  5. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE1

Show 2 earlier versions
  1. Oct 2024 — Jun 2025 [monthly]

    Recruiting PHASE1

    Status: Not Yet RecruitingRecruiting

  2. Sep 2024 — Oct 2024 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .